Equities research analysts at Evercore ISI began coverage on shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research note issued to investors on Wednesday, The Fly reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald restated a “buy” rating and issued a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Tuesday, May 9th. Maxim Group initiated coverage on GW Pharmaceuticals PLC in a research report on Thursday, April 20th. They set a “buy” rating and a $135.00 price target for the company. Zacks Investment Research upgraded GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price target for the company in a research report on Monday, July 17th. TheStreet cut GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research report on Wednesday, May 10th. Finally, BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. GW Pharmaceuticals PLC currently has an average rating of “Buy” and an average target price of $147.94.

GW Pharmaceuticals PLC (GWPH) traded up 0.41% on Wednesday, reaching $102.87. The company’s stock had a trading volume of 179,047 shares. GW Pharmaceuticals PLC has a 12-month low of $79.62 and a 12-month high of $137.88. The firm has a 50-day moving average of $107.42 and a 200 day moving average of $113.11. The company’s market capitalization is $2.61 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. The business had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same quarter last year, the firm earned ($0.05) earnings per share. On average, equities research analysts anticipate that GW Pharmaceuticals PLC will post ($5.55) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/16/gw-pharmaceuticals-plc-gwph-earns-outperform-rating-from-analysts-at-evercore-isi.html.

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. raised its position in shares of GW Pharmaceuticals PLC by 37.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,119 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 855 shares during the period. IHT Wealth Management LLC raised its position in shares of GW Pharmaceuticals PLC by 18.0% in the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 100 shares during the period. Redmile Group LLC raised its position in shares of GW Pharmaceuticals PLC by 33.8% in the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after buying an additional 112,392 shares during the period. State Street Corp acquired a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $212,000. Finally, Janus Henderson Group PLC acquired a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $70,128,000. 74.98% of the stock is currently owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

The Fly

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.